Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 15/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | LSS | P48449 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6299380 | 0.82 | F10 (0.66) | F10ATMSMN1; SMN2LMNAMAPT | |
| SCHEMBL6384691 | 0.78 | F10 (0.50) | F10ATMLSSSMN1; SMN2LMNA | |
| SCHEMBL7498568 | 0.77 | LSS (0.58) | F10LSSLMNA | |
| SCHEMBL6305931 | 0.77 | F10 (0.53) | F10F2 | |
| SCHEMBL6299264 | 0.74 | F10 (0.49) | F10ATMSMN1; SMN2LMNA | |
| SCHEMBL6298895 | 0.73 | F10 (0.51) | F10ATMSMN1; SMN2LMNA | |
| SCHEMBL6389239 | 0.72 | ATM (0.60) | F10ATMSMN1; SMN2LMNAF2 | |
| SCHEMBL5735220 | 0.72 | F10 (0.61) | F10ATMSMN1; SMN2LMNAMAPT | |
| SCHEMBL5733762 | 0.71 | F10 (0.72) | F10ATMSMN1; SMN2LMNA | |
| SCHEMBL6306256 | 0.71 | F10 (0.67) | F10ATMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6936610-B2 | Heterocyclic derivatives | ASTRAZENECA UK LIMITED (GB) | 2005-08-30 | — | — | US | disclosed |
| EP-0937048-B1 | HETEROCYCLE DERIVATIVES WHICH INHIBIT FACTOR Xa | ASTRAZENECA AB (SE) | 2004-01-21 | — | — | EP | disclosed |
| EP-1358909-A1 | Heteroaryl-phenyl derivatives as factor xa inhibitors for use as antithrombotic and anticoagulant agents | AstraZeneca AB (SE) | 2003-11-05 | — | — | EP | disclosed |
| US-20030195203-A1 | Heterocyclic derivatives | ASTRAZENECA UK LIMITED (GB) | 2003-10-16 | — | — | US | disclosed |
| US-6300330-B1 | BLOOD COAGULATION FACTOR X INHIBITORS AS ANTICOAGULANTS | ZENECA LIMITED (GB) | 2001-10-09 | — | — | US | disclosed |
| EP-0937048-A1 | HETEROCYCLE DERIVATIVES WHICH INHIBIT FACTOR Xa | ZENECA LIMITED (GB) | 1999-08-25 | — | — | EP | disclosed |
| WO-1998021188-A1 | HETEROCYCLE DERIVATIVES WHICH INHIBIT FACTOR Xa | ZENECA LIMITED (GB) | 1998-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195203-A1 | Heterocyclic derivatives | F12, F11, F2 | F10 5/4885ATM 3746/4885LSS 2507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.